|
1
|
Epstein JI: Mimickers of prostatic
intraepithelial neoplasia. Int J Surg Pathol. 18(Suppl): 142S–148S.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Montironi R, Mazzucchelli R, Algaba F and
Lopez-Beltran A: Morphological identification of the patterns of
prostatic intraepithelial neoplasia and their importance. J Clin
Pathol. 53:655–665. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Marzo AM, Platz EA, Sutcliffe S, Xu J,
Grönberg H, Drake CG, Nakai Y, Isaacs WB and Nelson WG:
Inflammation in prostate carcinogenesis. Nat Rev Cancer. 7:256–269.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Marzo AM, Marchi VL, Epstein JI and
Nelson WG: Proliferative inflammatory atrophy of the prostate:
Implications for prostatic carcinogenesis. Am J Pathol.
155:1985–1992. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Slaughter DP, Southwick HW and Smejkal W:
Field cancerization in oral stratified squamous epithelium;
clinical implications of multicentric origin. Cancer. 6:963–968.
1953. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Braakhuis BJ, Tabor MP, Kummer JA, Leemans
CR and Brakenhoff RH: A genetic explanation of Slaughter's concept
of field cancerization: Evidence and clinical implications. Cancer
Res. 63:1727–1730. 2003.PubMed/NCBI
|
|
7
|
Dakubo GD, Jakupciak JP, Birch-Machin MA
and Parr RL: Clinical implications and utility of field
cancerization. Cancer Cell Int. 7:22007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Halin S, Hammarsten P, Adamo H, Wikström P
and Bergh A: Tumor indicating normal tissue could be a new source
of diagnostic and prognostic markers for prostate cancer. Expert
Opin Med Diagn. 5:37–47. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nonn L, Ananthanarayanan V and Gann PH:
Evidence for field cancerization of the prostate. Prostate.
69:1470–1479. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Trujillo KA, Jones AC, Griffith JK and
Bisoffi M: Markers of field cancerization: Proposed clinical
applications in prostate biopsies. Prostate Cancer.
2012:3028942012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haaland CM, Heaphy CM, Butler KS, Fischer
EG, Griffith JK and Bisoffi M: Differential gene expression in
tumor adjacent histologically normal prostatic tissue indicates
field cancerization. Int J Oncol. 35:537–546. 2009.PubMed/NCBI
|
|
12
|
Jones AC, Antillon KS, Jenkins SM, Janos
SN, Overton HN, Shoshan DS, Fischer EG, Trujillo KA and Bisoffi M:
Prostate field cancerization: Deregulated expression of macrophage
inhibitory cytokine 1 (MIC-1) and platelet derived growth factor A
(PDGF-A) in tumor adjacent tissue. PLoS One. 10:e01193142015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jones AC, Trujillo KA, Phillips GK, Fleet
TM, Murton JK, Severns V, Shah SK, Davis MS, Smith AY, Griffith JK,
et al: Early growth response 1 and fatty acid synthase expression
is altered in tumor adjacent prostate tissue and indicates field
cancerization. Prostate. 72:1159–1170. 2012. View Article : Google Scholar
|
|
14
|
Mora GR, Olivier KR, Cheville JC, Mitchell
RF Jr, Lingle WL and Tindall DJ: The cytoskeleton differentially
localizes the early growth response gene-1 protein in cancer and
benign cells of the prostate. Mol Cancer Res. 2:115–128.
2004.PubMed/NCBI
|
|
15
|
Pagel JI and Deindl E: Disease progression
mediated by egr-1 associated signaling in response to oxidative
stress. Int J Mol Sci. 13:13104–13117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gitenay D and Baron VT: Is EGR1 a
potential target for prostate cancer therapy? Future Oncol.
5:993–1003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Walia G, Pienta KJ, Simons JW and Soule
HR: The 19th annual Prostate Cancer Foundation scientific retreat.
Cancer Res. 73:4988–4991. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Delongchamps NB and Haas GP: Saturation
biopsies for prostate cancer: Current uses and future prospects.
Nat Rev Urol. 6:645–652. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eichler K, Hempel S, Wilby J, Myers L,
Bachmann LM and Kleijnen J: Diagnostic value of systematic biopsy
methods in the investigation of prostate cancer: A systematic
review. J Urol. 175:1605–1612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Presti JC Jr: Prostate biopsy strategies.
Nat Clin Pract Urol. 4:505–511. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rabbani F, Stroumbakis N, Kava BR, Cookson
MS and Fair WR: Incidence and clinical significance of
false-negative sextant prostate biopsies. J Urol. 159:1247–1250.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Patel AR and Jones JS: Optimal biopsy
strategies for the diagnosis and staging of prostate cancer. Curr
Opin Urol. 19:232–237. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pomerantz M: Active surveillance:
Pathologic and clinical variables associated with outcome. Surg
Pathol Clin. 8:581–585. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mazzucchelli R, Galosi AB, Santoni M,
Lopez-Beltran A, Scarpelli M, Cheng L and Montironi R: Role of the
pathologist in active surveillance for prostate cancer. Anal Quant
Cytopathol Histpathol. 37:65–68. 2015.PubMed/NCBI
|
|
25
|
Bellardita L, Valdagni R, van den Bergh R,
Randsdorp H, Repetto C, Venderbos LD, Lane JA and Korfage IJ: How
does active surveillance for prostate cancer affect quality of
life? A systematic review. Eur Urol. 67:637–645. 2015. View Article : Google Scholar
|
|
26
|
Kwon O and Hong S: Active surveillance and
surgery in localized prostate cancer. Minerva Urol Nefrol.
66:175–187. 2014.PubMed/NCBI
|
|
27
|
Lou DY and Fong L: Neoadjuvant therapy for
localized prostate cancer: Examining mechanism of action and
efficacy within the tumor. Urol Oncol. 34:182–192. 2016. View Article : Google Scholar
|
|
28
|
Lindner U, Lawrentschuk N, Schatloff O,
Trachtenberg J and Lindner A: Evolution from active surveillance to
focal therapy in the management of prostate cancer. Future Oncol.
7:775–787. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marshall S and Taneja S: Focal therapy for
prostate cancer: The current status. Prostate Int. 3:35–41. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Andreoiu M and Cheng L: Multifocal
prostate cancer: Biologic, prognostic, and therapeutic
implications. Hum Pathol. 41:781–793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pagel JI and Deindl E: Early growth
response 1 - a transcription factor in the crossfire of signal
transduction cascades. Indian J Biochem Biophys. 48:226–235.
2011.PubMed/NCBI
|
|
32
|
Adamson E, de Belle I, Mittal S, Wang Y,
Hayakawa J, Korkmaz K, O'Hagan D, McClelland M and Mercola D: Egr1
signaling in prostate cancer. Cancer Biol Ther. 2:617–622. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Adamson ED and Mercola D: Egr1
transcription factor: Multiple roles in prostate tumor cell growth
and survival. Tumour Biol. 23:93–102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Heldin CH: Autocrine PDGF stimulation in
malignancies. Ups J Med Sci. 117:83–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heldin CH: Targeting the PDGF signaling
pathway in tumor treatment. Cell Commun Signal. 11:972013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baron A, Migita T, Tang D and Loda M:
Fatty acid synthase: A metabolic oncogene in prostate cancer? J
Cell Biochem. 91:47–53. 2004. View Article : Google Scholar
|
|
37
|
Zadra G, Photopoulos C and Loda M: The fat
side of prostate cancer. Biochim Biophys Acta. 1831.1518–1532.
2013.
|
|
38
|
Husaini Y, Qiu MR, Lockwood GP, Luo XW,
Shang P, Kuffner T, Tsai VW, Jiang L, Russell PJ, Brown DA, et al:
Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer
development but increases metastases in TRAMP prostate cancer prone
mice. PLoS One. 7:e438332012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vaňhara P, Hampl A, Kozubík A and Souček
K: Growth/differentiation factor-15: Prostate cancer suppressor or
promoter? Prostate Cancer Prostatic Dis. 15:320–328. 2012.
View Article : Google Scholar
|
|
40
|
Bootcov MR, Bauskin AR, Valenzuela SM,
Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor
K, et al: MIC-1, a novel macrophage inhibitory cytokine, is a
divergent member of the TGF-beta superfamily. Proc Natl Acad Sci
USA. 94:11514–11519. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Karan D, Holzbeierlein J and Thrasher JB:
Macrophage inhibitory cytokine-1: Possible bridge molecule of
inflammation and prostate cancer. Cancer Res. 69:2–5. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Svaren J, Ehrig T, Abdulkadir SA,
Ehrengruber MU, Watson MA and Milbrandt J: EGR1 target genes in
prostate carcinoma cells identified by microarray analysis. J Biol
Chem. 275:38524–38531. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shim M and Eling TE: Protein kinase
C-dependent regulation of NAG-1/placental bone morphogenic
protein/MIC-1 expression in LNCaP prostate carcinoma cells. J Biol
Chem. 280:18636–18642. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mora GR, Olivier KR, Mitchell RF Jr,
Jenkins RB and Tindall DJ: Regulation of expression of the early
growth response gene-1 (EGR-1) in malignant and benign cells of the
prostate. Prostate. 63:198–207. 2005. View Article : Google Scholar
|
